---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038055"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:37:04.442470+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reports FY2023 net loss of $64.7M; Phase 2/3 trial paused, topline expected summer 2024

## Summary
- Net loss FY2023 $64.7M vs $41.0M prior year; Q4 net loss $16.9M vs $11.8M.
- Cash, equivalents and investments $134.5M at Dec 31, 2023.
- Phase 3 enrollment in epetraborole TR-MAC trial paused voluntarily Feb 2024 due to potentially lower efficacy; Phase 2 topline results expected summer 2024.
- Plan to discuss Phase 2/3 data with FDA; no safety concerns prompted pause.
- Executed license from UGA for Chagas disease candidate AN2-502998; Gates Foundation grant for TB/malaria.

## SEC filing metadata
- accession: 0000950170-24-038055
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017024038055/0000950170-24-038055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017024038055/antx-20240328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038055
- JSON: https://secwatch.observer/filing/0000950170-24-038055.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038055.txt

## Key facts
- Earnings Releases
  AN2 Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2023 results: net income Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year. Net loss for the fourth.
  - Period: the fourth quarter and year ended December 31, 2023
  - Net income: Net loss for the full year 2023 was $64.7 million, compared to $41.0 million in the prior year. Net loss for the fourth
  - Result: reported results
  source text: AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1880438/000095017024038055/0000950170-24-038055-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.